» Articles » PMID: 11689642

Replication-defective Vector Based on a Chimpanzee Adenovirus

Overview
Journal J Virol
Date 2001 Nov 2
PMID 11689642
Citations 114
Authors
Affiliations
Soon will be listed here.
Abstract

An adenovirus previously isolated from a mesenteric lymph node from a chimpanzee was fully sequenced and found to be similar in overall structure to human adenoviruses. The genome of this virus, called C68, is 36,521 bp in length and is most similar to subgroup E of human adenovirus, with 90% identity in most adenovirus type 4 open reading frames that have been sequenced. Substantial differences in the hexon hypervariable regions were noted between C68 and other known adenoviruses, including adenovirus type 4. Neutralizing antibodies to C68 were highly prevalent in sera from a population of chimpanzees, while sera from humans and rhesus monkeys failed to neutralize C68. Furthermore, infection with C68 was not neutralized from sera of mice immunized with human adenovirus serotypes 2, 4, 5, 7, and 12. A replication-defective version of C68 was created by replacing the E1a and E1b genes with a minigene cassette; this vector was efficiently transcomplemented by the E1 region of human adenovirus type 5. C68 vector transduced a number of human and murine cell lines. This nonhuman adenoviral vector is sufficiently similar to human serotypes to allow growth in 293 cells and transduction of cells expressing the coxsackievirus and adenovirus receptor. As it is dissimilar in regions such as the hexon hypervariable domains, C68 vector avoids significant cross-neutralization by sera directed against human serotypes.

Citing Articles

Advances of Recombinant Adenoviral Vectors in Preclinical and Clinical Applications.

Scarsella L, Ehrke-Schulz E, Paulussen M, Thal S, Ehrhardt A, Aydin M Viruses. 2024; 16(3).

PMID: 38543743 PMC: 10974029. DOI: 10.3390/v16030377.


An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza.

Xing M, Hu G, Wang X, Wang Y, He F, Dai W NPJ Vaccines. 2024; 9(1):64.

PMID: 38509167 PMC: 10954707. DOI: 10.1038/s41541-024-00857-5.


Both chimpanzee adenovirus-vectored and DNA vaccines induced long-term immunity against Nipah virus infection.

Lu M, Yao Y, Zhang X, Liu H, Gao G, Peng Y NPJ Vaccines. 2023; 8(1):170.

PMID: 37925490 PMC: 10625554. DOI: 10.1038/s41541-023-00762-3.


Molecular characterisation of human adenoviruses associated with respiratory infections in Uganda.

Ukuli Q, Erima B, Mubiru A, Atim G, Tugume T, Kibuuka H BMC Infect Dis. 2023; 23(1):435.

PMID: 37370005 PMC: 10294467. DOI: 10.1186/s12879-023-08403-9.


LEISH2b - A phase 2b study to assess the safety, efficacy, and immunogenicity of the Leishmania vaccine ChAd63-KH in post-kala azar dermal leishmaniasis.

Lacey C, Musa A, Khalil E, Younis B, Osman M, Wiggins R Wellcome Open Res. 2023; 7:200.

PMID: 37252616 PMC: 10213822. DOI: 10.12688/wellcomeopenres.17951.1.


References
1.
Basler C, Horwitz M . Subgroup B adenovirus type 35 early region 3 mRNAs differ from those of the subgroup C adenoviruses. Virology. 1996; 215(2):165-77. DOI: 10.1006/viro.1996.0019. View

2.
Yang Y, Trinchieri G, Wilson J . Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nat Med. 1995; 1(9):890-3. DOI: 10.1038/nm0995-890. View

3.
Athappilly F, Murali R, Rux J, Cai Z, Burnett R . The refined crystal structure of hexon, the major coat protein of adenovirus type 2, at 2.9 A resolution. J Mol Biol. 1994; 242(4):430-55. DOI: 10.1006/jmbi.1994.1593. View

4.
Guex N, Peitsch M . SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis. 1998; 18(15):2714-23. DOI: 10.1002/elps.1150181505. View

5.
Christ M, Louis B, Stoeckel F, Dieterle A, Grave L, Dreyer D . Modulation of the inflammatory properties and hepatotoxicity of recombinant adenovirus vectors by the viral E4 gene products. Hum Gene Ther. 2000; 11(3):415-27. DOI: 10.1089/10430340050015888. View